Reva Medical Gains CE Mark for Motiv Below-the-Knee Bioresorbable Scaffold


July 25, 2018—Reva Medical's Motiv drug-eluting bioresorbable scaffold has gained CE Mark approval for application in below-the-knee peripheral artery disease (PAD), the company announced. The Motiv scaffold is made from Tyrocore, a proprietary polymer Reva describes as being inherently radiopaque to ensure accurate placement. Reva's commercial platform also includes the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold.

The company expects initial cases to be performed in late 2018 or early 2019, and it will now select centers to further assess product performance and application while working to determine its complete PAD commercial strategy.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.